Notice Number: NOT-NS-20-036
Key Dates
Release Date: January 03, 2020
PA-18-917
Issued by
National Institute of Neurological Disorders and Stroke (NINDS)
Purpose
The purpose of this Notice is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) will participate, effective immediately, in PA-18-917 "Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)". This notice will be effective for the February 5, 2020 standard receipt date and subsequent due dates.
The following italicized changes are made to indicate the participation of NINDS in this FOA.
Currently Reads:
Part 1. Overview Information
Components of Participating Organizations
National Institute on Drug Abuse (NIDA)
National Cancer Institute (NCI))
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Aging (NIA)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.279, 93.393, 93.213, 93.273, 93.865, 93.866
Part 2. Full Text Announcement
Section I. Funding Opportunity Description
In addition to the topics listed above, additional specific areas of interest for some of the participating ICs are outlined below. Applicants are encouraged to contact the participating IC's Scientific/Research contact to discuss the submission and gauge the interest of the participating institute.
NIDA: Examine the role of various combinations and potencies of the two main cannabinoids (THC and CBD) and their effects on modulating the endocannabinoid system for pain perception and analgesia; effects of long-term endocannabinoid system therapies on addiction liability.
NCI: The role of cannabinoids and the endocannabinoid system in the treatment tumor-related pain conditions, such as metastatic bone pain, and painful conditions arising from the treatment of cancer, such as chemotherapy induced peripheral neuropathy, aromatase inhibitor arthralgias, and radiation induced stomatitis.
NCCIH: The role of naturally occurring phytocannabinoids and their derivatives either alone or in conjunction with other complementary approaches (e.g. other natural products, mind-body programs) in modulating the biological and neural systems associated with pain perception and analgesia in relevant model organisms or human subjects as well as the mechanisms underlying cannabinoid analgesic and anti-inflammatory properties. NCCIH will not fund research proposing efficacy or effectiveness clinical trials through this FOA (please see NCCIH Clinical Trial Funding Opportunities instead). Investigators are strongly encouraged to discuss their research plans with NCCIH program staff prior to submitting their application.
NICHD: Characterization of the cannabinoids and endocannabinoid system as potential targets for treatment of dysmenorrhea, vulvodynia, and chronic pelvic pain due to endometriosis and other gynecologic disorders. Studies into the role of these systems in the management of spasticity, neuropathic pain, bone pain, musculoskeletal pain and pain secondary to other disabling conditions. Cannabinoids and endocannabinoid system and their therapeutic and adverse effects in pregnancy and its outcomes.
NIAAA: Alcohol abuse/dependence causes increased pain sensitivity and neuropathic pain. The role of endocannabinoids in mediating the actions of alcohol in inducing and regulating pain responses will be the primary interest.
Modified to Read:
Part 1. Overview Information
Components of Participating Organizations
National Institute on Drug Abuse (NIDA)
National Cancer Institute (NCI))
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.279, 93.393, 93.213, 93.273, 93.853, 93.865, 93.866
Part 2. Full Text Announcement
Section I. Funding Opportunity Description
In addition to the topics listed above, additional specific areas of interest for some of the participating ICs are outlined below. Applicants are encouraged to contact the participating IC's Scientific/Research contact to discuss the submission and gauge the interest of the participating institute.
NIDA: Examine the role of various combinations and potencies of the two main cannabinoids (THC and CBD) and their effects on modulating the endocannabinoid system for pain perception and analgesia; effects of long-term endocannabinoid system therapies on addiction liability.
NCI: The role of cannabinoids and the endocannabinoid system in the treatment tumor-related pain conditions, such as metastatic bone pain, and painful conditions arising from the treatment of cancer, such as chemotherapy induced peripheral neuropathy, aromatase inhibitor arthralgias, and radiation induced stomatitis.
NCCIH: The role of naturally occurring phytocannabinoids and their derivatives either alone or in conjunction with other complementary approaches (e.g. other natural products, mind-body programs) in modulating the biological and neural systems associated with pain perception and analgesia in relevant model organisms or human subjects as well as the mechanisms underlying cannabinoid analgesic and anti-inflammatory properties. NCCIH will not fund research proposing efficacy or effectiveness clinical trials through this FOA (please see NCCIH Clinical Trial Funding Opportunities instead). Investigators are strongly encouraged to discuss their research plans with NCCIH program staff prior to submitting their application.
NICHD: Characterization of the cannabinoids and endocannabinoid system as potential targets for treatment of dysmenorrhea, vulvodynia, and chronic pelvic pain due to endometriosis and other gynecologic disorders. Studies into the role of these systems in the management of spasticity, neuropathic pain, bone pain, musculoskeletal pain and pain secondary to other disabling conditions. Cannabinoids and endocannabinoid system and their therapeutic and adverse effects in pregnancy and its outcomes.
NINDS: Interest is exclusively focused on the effect of the endogenous cannabinoid system in the neural mechanisms of pain and the transition from acute to chronic pain.
NIAAA: Alcohol abuse/dependence causes increased pain sensitivity and neuropathic pain. The role of endocannabinoids in mediating the actions of alcohol in inducing and regulating pain responses will be the primary interest.
All other aspects of this FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Michael Oshinsky, PhD
National Institute of Neurological Disorders & Stroke (NINDS)
Telephone: 301-496-9964
Email:michael.oshinsky@nih.gov
and Human Services (HHS)
